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Abstract Growth arrest specific (gas) 1 gene product is
expressed in non-transformed fibroblasts in response to stimuli
driving cells into Go phase. Gas1 has been demonstrated to
inhibit cell proliferation when over-expressed in proliferating
fibroblasts. This activity depends on a function of the p53 protein
independent of its transactivating ability. To better define the
pathway leading from Gas1, which is located on the plasma
membrane, to p53, we have undertaken a detailed characteriza-
tion of its topology. We demonstrate that the protein undergoes
cotranslational modifications in the endoplasmic reticulum,
consisting of signal peptide cleavage, N-linked glycosylation
and glycosyl-phosphatidylinositol anchor addition. Immunoelec-
tron microscopy shows that, in its mature form, Gas1 is
randomly distributed over the outer leaflet of the plasma
membrane and that upon antibody-induced clustering it relocal-
izes to caveolae. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
Key words: gas1 product; Growth inhibition;
GPI-anchored protein; p53 protein; Signal peptide
1. Introduction
When deprived of growth factors or grown at high cell
density, normal ¢broblasts leave the cell cycle and enter Go.
Under these conditions, an intrinsic program of gene expres-
sion is induced whereby a set of genes, called growth arrest
speci¢c (gas) genes, becomes highly expressed [1]. This pattern
of gene expression is reversible since growth-arrested ¢bro-
blasts, when coordinately reentering the cell cycle, down-reg-
ulate the expression of gas genes.
Gas1 has previously been shown to exert a growth sup-
pressing e¡ect when ectopically expressed both during syn-
chronous cell cycle reentry or during the exponential
growth/division cycle [2,3]. It has been demonstrated that
gas1 growth inhibitory e¡ect relies on a wt-p53 function in-
dependent of its transactivating functions [4]. Since Gas1 is a
plasma membrane protein [2,3], these evidences point to the
existence of a still uncharacterized pathway from the plasma
membrane to p53.
Primary amino acid sequence analysis and comparison be-
tween mouse and human gas1 cDNA predicted the existence
of two hydrophobic amino acid stretches, one at each termi-
nus of the protein [2,3]. Furthermore, a notable di¡erence
between the mouse and human sequence exists at the level
of the initiating methionine. We thus wanted to better de¢ne
the domains responsible for Gas1 interaction with the plasma
membrane and the resulting topology of the protein with re-
spect to the plane of the membrane.
Here we report that the N-terminal hydrophobic amino
acid stretch represents a signal peptide, required to target
the nascent peptide to the endoplasmic reticulum (ER) where
it is cleaved o¡. Next we demonstrate that the C-terminal
hydrophobic amino acid stretch represents a consensus se-
quence for the glycosyl-phosphatidylinositol (GPI) anchor
substitution, tethering Gas1 to the plasma membrane. Immu-
noelectron microscopy (EM) analysis revealed a random dis-
tribution of Gas1 upon the plasma membrane, which becomes
segregated into caveolae when anti-Gas1 antibodies are added
before ¢xation.
2. Materials and methods
2.1. Plasmid construction
The pGDSV7S gas1-Met1 construct was obtained by cloning a
BamHI/EcoRI gas1 cDNA 1.8 kb fragment into the BamHI/EcoRI
sites of the pGDSV7S vector [5]. The pGDSV7S gas1-Met42 construct
was obtained by PCR ampli¢cation of a NotI/BamHI 1.4 kb gas1
cDNA fragment cloned into the NotI/BamHI sites of pGDSV7S.
The pGDSV7S gas1-Met65 construct was obtained by site-directed
mutagenesis of the methionine at position 42. gas1 therefore was
ampli¢ed using two synthetic oligonucleotide primers both harboring
an ACT substitution thus modifying the ATG codon to a TTG
codon (Leu). The primers were used to amplify a 5P and a 3P fragment
of gas1 ; the two ampli¢ed fragments were puri¢ed from agarose gel
and used as templates to amplify the entire gas1-Met65 fragment
which was cloned into the NotI/EcoRI sites of the pGDSV7S vector.
For in vitro translation experiments, the same fragments were PCR-
ampli¢ed so that the respective methionines could be cloned in frame
substituting the viral methionine in position +5 of the pCITE-1 vector
(Novagen, Madison, WI, USA) which corresponds to the NcoI site in
the vectors polylinker.
2.2. Cell culture and transfections
NIH3T3 and COS7 cells were grown in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum (FCS)
(DMEM+10% FCS) and serum-starved as described [2]. Transfection
of NIH3T3 cells was performed with 8 Wg of DNA/8U104 cells using
the calcium-phosphate transfection procedure [6]. Transfection of
COS7 cells was performed with 2 Wg of DNA/35 mm plate using
the DEAE-dextran procedure [6].
2.3. In vitro translation
The in vitro translation experiments were performed using the TnT
rabbit reticulocyte system (Promega) according to the manufacturer’s
instructions. Trypsin (Boehringer) digestion was performed at 0‡C
for 1 h at a ¢nal trypsin concentration of 1 mg/ml. Soybean K1
anti-trypsin (¢nal concentration: 5 mg/ml, Boehringer) was added to
stop the reaction. Deglycosylation with peptide-N-glycosidase F
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(PNGase F, Oxford GlycoSystems), at the concentration of 100 U/ml,
was performed on the trypsin-treated product according to manufac-
turer’s instructions, after trypsin inactivation. For membrane trans-
location analysis, translation was performed in the presence of dog
pancreatic microsomes (DPM, New England Nuclear) [2]; micro-
somes were lysed by the detergent contained in the bu¡er supplied
for PNGase F treatment ¢nally performed.
2.4. Antibody preparation and Western blot analysis
Peptides were synthesized according to the Fmoc solid phase pep-
tide synthesis [7], and were designed to span Gas1 amino acids: 2^14
(‘Pep 1’); 337^356 (‘337’). Peptides were puri¢ed by reverse-phase
FPLC. The recombinant protein QE 229 was generated by cloning
the gas1 cDNA fragment spanning amino acids 229^342 into the
expression vector pQE-11 (Qiagen) in frame with 5P pQE [His]6 tag.
The recombinant protein was produced as suggested by the manufac-
turer and puri¢ed on Ni-NTA resin. The puri¢ed recombinant protein
and the KLH crosslinked peptides were injected in rabbits to raise
speci¢c antisera. Antibodies were a⁄nity-puri¢ed on columns coupled
with peptides or with the recombinant protein using respectively Sul-
foLink Coupling Gel (Pierce) or A⁄-Prep 10 (Bio-Rad) according to
the manufacturer’s instructions. A⁄nity-puri¢ed antibodies are re-
ferred to as ‘anti-Pep 1’, ‘anti-337’ and ‘anti-QE 229’.
Mouse monoclonal ‘anti-caveolin’ antibody was purchased from
Transduction Laboratories. Rabbit anti-human placental alkaline
phosphatase (‘anti-hPLAP’) antibody was purchased from Dako,
Denmark. Rabbit anti-cross reacting determinant (‘anti-CRD’) anti-
body was included in the ‘GPI anchor detection kit’ purchased from
Oxford GlycoSystems. Western blot analysis was performed as de-
scribed [2].
2.5. Cell labelling procedures and immunoprecipitations
[9,10-3H]Palmitic acid (54 Ci/mmol, Amersham) dissolved in etha-
nol was dried in a Speed Vac concentrator (Savant) using silanized
Eppendorf tubes and resuspended in DMEM+10% FCS.
Transfected COS cells were labelled with [9,10-3H]palmitic acid
(200 WCi/ml) for 10^12 h. Sodium pyruvate 5 mM was added to limit
palmitic acid conversion to amino acids. Cells were lysed with
TBS+0.8% sodium dodecyl sulfate (SDS) (Tris^HCl 50 mM, pH
7.5, NaCl 150 mM, SDS 0.8%) and diluted with an equal volume of
TBS+2% Triton X-100.
Transfected COS cells were starved for methionine 1 h before ad-
dition of 150 WCi/ml of [35S]methionine (Amersham), labelled for 5 h
and lysed as above.
Preclearing of cell lysates was made with non-immune rabbit IgG
and Immuno-Precipitine (Gibco BRL); immunoprecipitation was per-
formed with anti-QE 229 antibody where not di¡erently speci¢ed, at
1 Wg/ml for 2^4 h at 4‡C; immunoprecipitates were resolved on SDS^
polyacrylamide gel electrophoresis (SDS^PAGE) [8].
2.6. Phosphatidylinositol speci¢c phospholipase C (PI-PLC) digestion
hPLAP-transfected NIH3T3 cells were growth-arrested by serum
deprivation; cells were collected in phosphate-bu¡ered saline (PBS)
by scraping, pelleted and resuspended in 100 Wl of lysis bu¡er (PBS
containing: Triton X-114 0.1%, EDTA 5 mM, 20 Wg/ml of leupeptin,
pepstatin, antipain and chymostatin). To analyze cell lysates, the ‘GPI
anchor detection kit’ was used according to the manufacturer’s in-
structions. For PI-PLC digestion on plate, pGDSV7S gas1-Met42-
transfected COS7 cells from one 35 mm dish were grown for an addi-
tional 24 h in DMEM+10% fetal bovine serum and then replated in
48-well tissue culture microtiter plates (Costar, 1 ml/well). 24 h later,
70 Wl of PI-PLC bu¡er (Tris^HCl 25 mM, pH 7.5, sucrose 250 mM,
glucose 10 mM, CaCl2 0.5 mM, MgCl2 0.5 mM) was added to each
well, with or without PI-PLC (5 U/ml). Digestion was performed at
37‡C for 1 h; the medium from seven wells was pooled and proteins
were concentrated by ultra¢ltration in Amicon Microcon (MWCO
10 000) up to the dead volume. Samples were then subjected to
SDS^PAGE and Western blot.
2.7. Immunoelectron microscopy
NIH3T3 cells were grown on plastic coverslips in the presence of
10% FCS or serum-starved for 48 h in 0.5% FCS. Cells were surface-
labelled with a⁄nity-puri¢ed antibodies to Gas1 followed by 10 nm
protein A-gold either after pre¢xation with 0.1% glutaraldehyde in
100 mM cacodylate bu¡er or at 4‡C before ¢xation. Fixation and
further processing were exactly as described previously [9,10].
3. Results and discussion
3.1. Analysis of Gas1 protein processing
The murine gas1 cDNA (GenBank X65128-MMGASIMR)
open reading frame contains at least three putative initiating
methionines at positions 1, 42 and 65. Comparison with the
human gas1 sequence (GenBank L13698) (Fig. 1A) reveals
that only methionines 42 and 65 are conserved [3].
To test if the two latter methionines represent initiation
sites for translation, two constructs of murine gas1 were pro-
duced (Fig. 1B): the ¢rst contained a deletion of the amino
acids 1^41, thus starting with methionine 42 (gas1-Met42); the
other construct derived from the former but with a 42Met-
CLeu substitution leaving only Met65 available for transla-
tion (gas1-Met65). COS7 cells, not expressing endogenous
Gas1 (Fig. 2A, lane e), were transfected with the three
pGDSV7S plasmids encoding gas1-Met1, gas1-Met42 and
gas1-Met65, lysed and immunoprecipitated with anti-Gas1
antibody. Fig. 2A shows that the murine gas1 cDNA starting
Fig. 1. Partial Gas1 protein sequence, construct maps and antibody
epitopes are shown. (A) Alignment of murine and human Gas1 ami-
no acid sequences restricted to the amino- and carboxy-terminal re-
gions involved in cotranslational modi¢cation. Hydrophobic regions
are underlined; asterisks represent candidate cleavage sites of the
signal peptide; dots indicate candidate amino acids undergoing GPI
anchor addition. (B) Wild type gas1 cDNA (gas1-Met1) was cleaved
before Met42 to produce the deletion gas1-Met42. A second con-
struct was derived from gas1-Met42 by site-directed mutagenesis
leading to a 42MetCLeu substitution giving raise to gas1-Met65.
Bold bars indicate the epitopes against which antibodies were raised
(see Section 2 for details).
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with Met1 or Met42 can successfully initiate translation in
vivo (lanes b and c), while Met65 is completely ine¡ective,
either in vivo (lane d) or in vitro (not shown). The mature
proteins as ectopically synthesized in COS7 cells had an ap-
parent molecular weight similar to the endogenous Gas1 ex-
pressed by resting NIH3T3 cells (lane a), thus indicating that
either the initiating methionine is Met42 in both cases or that,
if Met1 is used, further processing leads to a product with
similar electrophoretic mobility.
To analyze the N-terminal requirement in the initial pro-
cessing steps, membrane insertion and topology of Gas1 was
studied in an in vitro translation system using the pCITE
gas1-Met1 and pCITE gas1-Met42 constructs, the pCITE vec-
tors strictly allowing for the methionine placed after CITE
sequence to initiate translation.
As shown in Fig. 2B, the pCITE-driven in vitro translation
resulted in two primary products (lanes a and e) with an
expected di¡erence in relative mobility due to gas1-Met1 con-
taining 41 amino acids more than gas1-Met42. In vitro trans-
lation in the presence of DPM with subsequent trypsin diges-
tion is an established method to select for proteins fully
translocated into the membranes, since they become protected
from the action of the protease. Under these conditions, trans-
lation of both cDNAs resulted in a lower and similar sized
band for both pCITE gas1-Met1 and pCITE gas1-Met42
(lanes b and f), with a molecular weight similar to that of
the endogenous Gas1. We therefore hypothesize that such a
band corresponds to the form of the protein as processed in
the ER. To con¢rm that the resulting product was fully pro-
tected, trypsin digestion carried out in the presence of the
detergent NP40 resulted in the complete disappearance of
the respective products (lanes d and h). Treatment of the
detergent-unmasked product with the PNGase F resulted in
a faster migrating band, thus demonstrating that the Gas1 in
vitro translated product is N-glycosylated (lanes c and g).
Immunoprecipitation was performed with ‘anti-Pep 1’ anti-
body on the in vitro translation products as obtained from
gas1-Met1 and gas1-Met42 either in the absence of DPM or
in the presence of DPM followed by trypsinization. This anti-
body recognizes only the product of gas1-Met1 translated in
the absence of DPM (lane i), while it fails to immunoprecipi-
tate either the gas1-Met42 product (lanes k and l) (not con-
Fig. 2. Biochemical analysis of Gas1. (A) COS cells were transfected with either pGDSV7S gas1-Met1 (b), pGDSV7S gas1-Met42 (c) or
pGDSV7S gas1-Met65 (d). Lysates from transfected and not transfected (e) COS cells and from resting NIH3T3 cells (a) were immunoprecipi-
tated with ‘anti-229’ antibody and resolved on SDS^PAGE. (B) pCITE gas1-Met1 and pCITE gas1-Met42 were used for in vitro translation ex-
periments. Translation was performed in the absence (a and e) or in the presence of DPM followed by trypsin digestion without (b and f) or
with previous solubilization with NP40 (d and h). Translation products were solubilized and digested with PNGase F (c and g). (i^l) Immuno-
precipitation with ‘anti-Pep 1’ antibody of in vitro translation products corresponding respectively to lanes a, b, e and f. See text for details.
Fig. 3. Gas1 palmitoylation and PI-PLC digestion. (A) pGDSV7S gas1-Met42-transfected COS cells were labelled either with [35S]methionine
(a) or with [3H]palmitic acid (b). Cells were lysed and immunoprecipitated with ‘anti-229’ antibody. Immunoprecipitates were resolved on SDS^
PAGE. (B) hPLAP-transfected, serum-starved NIH3T3 cells were recovered in 100 Wl of PI-PLC bu¡er. 50 Wl aliquots were treated with (a and
b) or without (c and d) PI-PLC and subjected to Triton X-114 phase separation (see text for details). The aqueous (a and c) and the detergent
(b and d) phases were resolved on SDS^PAGE, blotted and probed with either ‘anti-hPLAP’, ‘anti-229’ or ‘anti-caveolin’ antibodies as indi-
cated. (C) pGDSV7S gas1-Met42-transfected (a) and not transfected (b) COS cells were treated on plate with PI-PLC. Supernatant was col-
lected, concentrated, electrophoresed and blotted. The membrane was probed with ‘anti-CRD’ antibody.
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taining the epitope), or the gas1-Met1 protein after processing
in the membranes (lane j). This antibody also fails to recog-
nize the endogenous Gas1 from NIH3T3 as well (not shown).
From these data, we conclude that in vitro primary trans-
lation products starting either from the ¢rst or the second
methionine are similarly processed by the microsomal fraction
to a protein with similar mobility as the in vivo gas1 product.
The predicted murine protein sequence from Arg52 to
Arg85 was analyzed on the basis of the weight matrix cal-
culated by von Heijne [11] to predict signal sequence cleavage
sites. Pro75, Gly77, Ala74 and Leu80 were found as possible
sites of cleavage. Proline is suggested to be absent from 33
through +1 relative to the mature form and Ala74 and Leu80
only ful¢ll this requirement, thus potentially representing the
¢rst amino acids of the mature Gas1. The results of this
analysis are in agreement with the presented experimental
data.
The data presented exclude the presence of a transmem-
brane domain at the N-terminus of the mature protein. It
follows that Gas1 relies only on the C-terminal hydrophobic
stretch to anchor to the plasma membrane. The absence of a
hydrophilic sequence following the putative transmembrane
domain hints at the presence of a GPI moiety substituting
the amino acid stretch.
The GPI anchor contains ethanolamine, a short glycosidic
chain, a myo-inositol and a diacyglycerolphosphate [12]. We
¢rst tested whether in vivo Gas1 could incorporate fatty acids.
COS cells were transfected with pGDSV7S gas1-Met42 and
separately labelled with [3H]palmitate and [35S]methionine.
Gas1 was immunoprecipitated from cell lysates and separated
on SDS^PAGE; Fig. 3A shows that it incorporated
[3H]palmitate (lane b).
GPI-anchored proteins are sensitive to PI-PLC digestion
thus behaving as soluble proteins [12]. NIH3T3 cells were
transfected with hPLAP, a well studied GPI-anchored protein
[13], solubilized in a bu¡er containing Triton X-114 and di-
gested with PI-PLC. Following addition of 2% ¢nal Triton
X-114 and temperature-induced phase separation, aqueous
and detergent phases were analyzed by immunoblotting
(Fig. 3B). Compared to the undigested control, where Gas1
Fig. 4. EM analysis of surface labelling of Gas1 in resting or dividing NIH3T3 cells. Resting (a and b) or proliferating (c) NIH3T3 cells were
¢xed with 0.1% glutaraldehyde and labelled with ‘anti-229’ antibody followed by 10 nm protein A-gold. In the resting cells (a and b), heavy
gold labelling is evident over the entire cell surface. In contrast, negligible labelling is observed on the surface of dividing cells labelled under
identical conditions (c, gold particle indicated by large arrowhead). Caveolae (60 nm uncoated surface invaginations) are indicated by small ar-
rowheads. Bar = 100 nm.
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is retained in the detergent phase (lane d), PI-PLC treatment
totally released the Gas1 protein into the aqueous phase (lane
a). hPLAP similarly proved sensitive to the digestion while
caveolin, a transmembrane protein endogenously expressed
by NIH3T3 cells [14], was totally retained in the detergent
phase. Similar results were obtained for the human Gas1 pro-
tein when expressed in COS cells (not shown). The complete
release of the Gas1 protein from the membrane fraction into
the aqueous phase by PI-PLC treatment indicates that the
whole of the mature protein is GPI-anchored.
Following PI-PLC digestion of GPI-anchored proteins, the
remaining myo-inositol phosphate cyclizes, creating a new epi-
Fig. 5. EM analysis of surface labelling of Gas1 in resting NIH3T3 cells with or without pre¢xation. Resting NIH3T3 cells were labelled after
pre¢xation with glutaraldehyde as in (a) or were labelled at 4‡C with ‘anti-229’ antibody and 10 nm protein A-gold prior to ¢xation (b and c).
(a) (pre¢xation) shows a section across the cell surface; labelling for Gas1 is distributed almost randomly over the entire cell surface including
coated pits (double arrowheads) and caveolae (arrowheads). Surface projections (arrow) are particularly heavily labelled. Cells labelled before
¢xation (b and c) show a clear concentration of gold particle clusters within caveolae (arrowheads). Labelling is rarely observed in coated pits
(e.g. see coated pit/vesicle indicated by double arrowheads in c). Bar = 100 nm.
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tope called CRD, against which a speci¢c antibody is avail-
able.
pGDSV7S gas1-Met42-transfected COS cells and a non-
transfected control were digested with PI-PLC on plate; the
supernatant was concentrated, separated on SDS^PAGE and
analyzed with an ‘anti-CRD’ antibody by Western blot. As
shown in Fig. 3C, a positive band to this antibody was de-
tected only in the supernatant corresponding to the trans-
fected and PI-PLC-treated cells at the height of Gas1 (lane
a), while the PI-PLC-treated untransfected control was nega-
tive (lane b). Stripping of the membrane and reprobing with
‘anti-229’ antibody resulted in a signal completely superim-
posable to the former band (not shown).
From these evidences, we conclude that Gas1 in its mature
form is inserted in the plasma membrane through a GPI an-
chor at its carboxy-terminus.
Inspection of the primary amino acid sequence of the car-
boxy-terminus of the murine Gas1 (Fig. 1A) con¢rmed the
presence of a consensus sequence for the GPI modi¢cation
[15,16]; more speci¢cally Ser353 and Ser356 represent the
most probable candidate acceptor sites. Such consensus is
also present in the human homologue at Ser317 and Ser318.
Localization of the GPI consensus at this site agrees with the
results obtained when using the ‘anti-337’ antibody, whose
epitope ends at Ser356 of the murine protein. This antibody
in fact recognizes the mature protein product (not shown),
thus indicating that the protein cleavage for GPI substitution
conserves such an epitope.
3.2. Plasma membrane localization
Immunoelectron microscopy was used to investigate the
distribution of Gas1 on the plasma membrane and to quanti-
tate the relative expression in growth-arrested versus prolifer-
ating ¢broblasts.
NIH3T3 cells cultured under the two di¡erent conditions
were ¢xed and immunolabelled with ‘anti-229’ antibody.
Under resting conditions, a strong signal was present on the
plasma membrane (Fig. 4a,b). In contrast, proliferating cells
labelled in parallel showed extremely low labelling (Fig. 4c). A
quantitative analysis of the gold labelling density showed a
more than 20-fold higher level of Gas1 on the plasma mem-
brane in growth-arrested cells (22 particles/Wm2) than in pro-
liferating cells (0.9 particles/Wm2).
Previous studies have described a concentration of GPI-an-
chored proteins in surface caveolae [17]. In contrast, more
recent studies suggest that GPI-anchored proteins normally
show a random distribution over the cell surface but are re-
distributed into caveolae on crosslinking with antibodies be-
fore ¢xation [17,18]. We therefore examined the surface dis-
tribution of Gas1 with or without a glutaraldehyde pre¢xation
step.
Fig. 5a (see also Fig. 4a,b) shows that labelling for Gas1 is
almost randomly distributed over the plasma membrane, in-
cluding caveolae and coated pits, when cells are ¢xed before
labelling. We assume that no further mobility and/or cluster-
ing are induced by the antibody after glutaraldehyde ¢xation
and therefore that this labelling pattern represents the natural
distribution of Gas1.
Fig. 5b,c shows that the pattern is completely di¡erent
when cells are immunolabelled at 4‡C before ¢xation: gold
particles are not randomly spread over the entire plasma
membrane but are found as clusters within caveolae. Labelling
was rarely seen within clathrin coated pits under these con-
ditions. It therefore appears that clustering of Gas1 within
caveolae is increased upon crosslinking with ‘anti-229’ anti-
bodies.
Increasing evidence has demonstrated that GPI anchors
target the proteins to plasma membrane ‘rafts’ rich in glyco-
sphingolipids, sphingomyelin and cholesterol. Such a compo-
sition is only partially solubilized by common non-ionic de-
tergents at 4‡C, resulting in GPI-anchored proteins
partitioning into detergent-insoluble glycosphingolipid-en-
riched complexes (DIG) [19]. This property also holds true
for Gas1 (not shown). Similar detergent insolubility of these
rafts and caveolae [14,20] has allowed the copuri¢cation of
GPI-anchored proteins with caveolar markers, namely caveo-
lin [20,21]. These biochemical evidences have led to the as-
sumption that detergent-insoluble complexes correspond to
plasma membrane caveolae [20] ; however, this assumption
has been questioned on the basis of (a) the presence of
GPI-linked proteins in detergent-insoluble complexes in lym-
phocytes, which lack caveolae [22], and (b) a di¡erent bio-
chemical procedure to isolate caveolae from the rest of the
plasma membrane, whereby GPI-anchored proteins appear to
reside only at the neck of, but not inside, caveolae [23].
Immunoelectron microscopy analysis, showing Gas1 ran-
domly distributed all over the plasma membrane without ei-
ther particular inclusion or association to the neck of caveo-
lae, con¢rms the interpretation that DIGs and associated
proteins are not necessarily localized to caveolae. Other,
more speci¢c, protein^protein interactions should account
for GPI-anchored protein localization.
It has been demonstrated that antibodies against GPI-an-
chored proteins, when added to cells before ¢xation, induce
clustering of the proteins and their relocalization into caveolae
[11,18] ; in lymphocytes, such an antibody-induced clustering
of GPI-anchored proteins results in cell activation, correlated
with Tyr phosphorylation of Src and Src-like kinases [24,25].
Although EM analysis con¢rms such an antibody-induced
redistribution for Gas1 as well, we have not found any evi-
dence indicating that treatment of growth-arrested NIH3T3
cells with anti-Gas1 antibody elicits a speci¢c phosphorylation
pattern.
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